Navigation Links
New research network for multiple sclerosis research
Date:1/14/2013

To date, Multiple Sclerosis (MS) has been considered to be an incurable disease involving the immune system and its exact causes are still unknown. Why exactly is there inadequate communication between the various kinds of immune cells in patients with the autoimmune disease MS? Why are the brains of MS patients the targets of "accidental" attacks by their own immune system? It is hoped that the research network ITN-NeuroKine, currently in the process of being formed under the aegis of the University Medical Center of Johannes Gutenberg University Mainz (JGU) with the help of EUR 3.5 million in funding provided by the European Commission, will provide answers to these questions. ITN stands for Initial Training Network, a concept established as one of the Marie Curie Actions and designed to promote European networks for the structured training of young researchers. 'NeuroKine' is an acronym for 'Neurological disorders orchestrated by cytoKines'. The ITN NeuroKine network was launched on January 1, 2013.

"The core objective of our new ITN-NeuroKine research network is to gain insight into the impairment of communication between immune cells," explained Professor Dr. Ari Waisman, Director of the Institute of Molecular Medicine (IMM) at the Mainz University Medical Center. "We will specifically be focusing on the soluble proteins called cytokines, which regulate the communication between these cells." Immune cells are mobile and are present at various sites in the body.

The ITN-NeuroKine research network is composed of an international team of researchers with a broad range of expertise in the areas of molecular and cellular neuroimmunology and neuropathology. The participants are scientists from the University of Zrich (UZH), the Medical University of Vienna (MUW), the Parisian Institut National de la Sant et de la Recherche Mdicale (INSERM), the Universit Vita-Salute San Raffaele (USR) in Milan, the Weizmann Institute of Science (WIS) based in Rehovot, Israel, the Erasmus University Medical Center in Rotterdam (EMC), and the Charit University Hospital in Berlin together with various commercial medical organizations, such as Miltenyi Biotech GmbH, Apitope Technology Ltd., Phenex Pharmaceuticals AG, and the Mainz-based BioNTech AG. Also participating are the Postdoc Career Development Initiative (PCDI) in Utrecht, the Novartis Institutes for BioMedical Research in Basel, and GlaxoSmithKline.

"The creation of the ITN-NeuroKine research network is crucial to the reputation of Mainz as a science hub. On the one hand, the ITN-NeuroKine network will be conducting cutting-edge research into the area where brain and immune system interact. At the same time, this network will be providing young researchers with the opportunity to receive specialized training," emphasized Professor Dr. Dr. Reinhard Urban, Chief Scientific Officer of the Mainz University Medical Center.


'/>"/>
Contact: Dr. Rene Dillinger-Reiter
pr@unimedizin-mainz.de
49-613-117-7424
Johannes Gutenberg Universitaet Mainz
Source:Eurekalert

Related biology news :

1. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
2. Research reveals first evidence of hunting by prehistoric Ohioans
3. Diabetes Research Institute develops oxygen-generating biomaterial
4. APS issues new policy requiring identification of sex or gender in reporting scientific research
5. UC Santa Barbara researchers discover genetic link between visual pathways of hydras and humans
6. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
7. U of Alberta researcher steps closer to understand autoimmune diseases
8. Research on flavanols and procyanidins provides new insights into how these phytonutrients may positively impact human health
9. A project to research biological and chemical aspects of microalgae to fuel approach
10. Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
11. Researchers attempt to solve problems of antibiotic resistance and bee deaths in one
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/9/2017)... and MOUNTAIN VIEW, Calif. , March ... Made Simple," and 23andMe , the leading personal ... food choices.  Zipongo can now provide customers with personalized ... health goals and biometrics, but also genetic markers impacting ... Zipongo,s personalized food decision support platform uses ...
(Date:3/2/2017)... 2017 Summary This report provides all ... partnering interests and activities since 2010. ... Read the full report: ... 2010 report provides an in-depth insight into the partnering activity ... On demand company reports are prepared upon purchase to ...
(Date:3/1/2017)... March 1, 2017  Aware, Inc. (NASDAQ: AWRE), a ... Richard P. Moberg has resigned, effective March ... Chief Financial Officer and Treasurer of Aware citing a ... as a member of the Board of Directors of ... co-Chief Executive Officer and co-President, General Counsel has been ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... -- In today,s pre-market research, Stock-Callers.com takes ... industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate Pharmaceuticals Inc. ... Regulus Therapeutics Inc. (NASDAQ: RGLS ). On ... rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn more about ... ...
(Date:3/22/2017)... 2017  UBM and the Massachusetts Medical Device ... partnership and the third annual Massachusetts Medtech Week. Massachusetts ... st Annual MassMEDIC Conference held in conjunction ... 2017. MassMEDIC will feature a ... and CEO, Scott Whitaker , at its ...
(Date:3/22/2017)... Florida , March 22, 2017 ... ... various cancer conditions are being pressured as of late due ... for cancer pain management has a dramatic impact on patient,s ... research and development activities for identifying new forms of opioid ...
(Date:3/22/2017)... ... March 21, 2017 , ... Okyanos Cell Therapy has announced Tallahassee, ... their live events series, “Stem Cell Therapy: The Next Phase in the Evolution of ... Stem Cell Research and Therapy Act, Okyanos maintains a mission to help ...
Breaking Biology Technology: